Is LIVN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Epilepsy pricing and reimbursement reset, with revenue (ttm) at ~$1.47 billion. The bear case rests on the largest single item is the SNIA environmental case in Italy, where the Italian Supreme Court ruled in March 2025 that LivaNova can be held jointly and severally liable for SNIA's pre-demerger environmental liabilities, leading the company to record roughly 333 million euros (about $360 million) as its best estimate; the balance sheet carried roughly 345.5 million euros of current liability as of March 31, 2026, and the Public Administrations have asserted a minimum of 108.8 million euros in additional costs on remand to the Court of Appeal of Milan, so the final number and its timing are still open. Analysts covering it are spread from $67.00 to $95.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest single item is the SNIA environmental case in Italy, where the Italian Supreme Court ruled in March 2025 that LivaNova can be held jointly and severally liable for SNIA's pre-demerger environmental liabilities, leading the company to record roughly 333 million euros (about $360 million) as its best estimate; the balance sheet carried roughly 345.5 million euros of current liability as of March 31, 2026, and the Public Administrations have asserted a minimum of 108.8 million euros in additional costs on remand to the Court of Appeal of Milan, so the final number and its timing are still open. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $67.00, -14.3% from the $78.14 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Epilepsy pricing and reimbursement reset. Effective January 1, 2026, CMS assigned new VNS Therapy implants to New Technology Ambulatory Payment Classification 1580, lifting Medicare reimbursement for the procedure by nearly 50% versus 2025. The most optimistic analyst target on LIVN is $95.00, +21.6% from the $78.14 price. That figure is only reachable if this thesis works close to its best case.

The largest single item is the SNIA environmental case in Italy, where the Italian Supreme Court ruled in March 2025 that LivaNova can be held jointly and severally liable for SNIA's pre-demerger environmental liabilities, leading the company to record roughly 333 million euros (about $360 million) as its best estimate; the balance sheet carried roughly 345.5 million euros of current liability as of March 31, 2026, and the Public Administrations have asserted a minimum of 108.8 million euros in additional costs on remand to the Court of Appeal of Milan, so the final number and its timing are still open. Free cash flow guidance was cut to $140 million to $160 million while capital spending was raised to $135 million, meaning near-term cash conversion is being deliberately sacrificed for 2027 capacity, and any execution slip on that production line pushes the payoff out. Concentration risk is real: two segments, one implant franchise and one bypass hardware franchise, with no third leg to absorb a shortfall, and cardiopulmonary revenue is tied to open-heart surgical procedure volumes that LivaNova does not control. The obstructive sleep apnea entry puts the company against Inspire Medical's entrenched physician network and payer coverage plus Nyxoah's leadless Genio system, and building surgeon adoption and reimbursement from zero is expensive and slow. Finally, the shares fell roughly 8% on August 5, 2026 despite beating on both revenue and earnings and raising guidance, a reminder that at roughly 18x forward earnings the stock is not priced as a distressed asset and reacts sharply when the cash flow line disappoints. The most pessimistic published target is $67.00, -14.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

LivaNova is a UK-incorporated, Nasdaq-listed medical technology company built around cardiopulmonary bypass equipment and vagus nerve stimulation for epilepsy and depression.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Epilepsy pricing and reimbursement reset) stalling in the reported numbers rather than in the narrative, the risk above (the largest single item is the SNIA environmental case in Italy, where the Italian Supreme Court ruled in March 2025 that LivaNova can be held jointly and severally liable for SNIA's pre-demerger environmental liabilities, leading the company to record roughly 333 million euros (about $360 million) as its best estimate; the balance sheet carried roughly 345.5 million euros of current liability as of March 31, 2026, and the Public Administrations have asserted a minimum of 108.8 million euros in additional costs on remand to the Court of Appeal of Milan, so the final number and its timing are still open) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

LivaNova is a medical technology company with two segments. Cardiopulmonary makes the equipment used during open-heart surgery, including heart-lung machines (the Essenz Perfusion System), oxygenators, autotransfusion systems and perfusion tubing. Neuromodulation makes the VNS Therapy implant that stimulates the vagus nerve to treat drug-resistant epilepsy, plus development programs in difficult-to-treat depression and the FDA-approved aura6000 implant for moderate to severe obstructive sleep apnea.

LIVN trades on the Nasdaq, so you can buy whole or fractional shares at any major US broker. It is also held inside small-cap and healthcare-equipment index funds, which is the lower-concentration route. Because the company is UK-incorporated but Nasdaq-listed and reports in US dollars, it trades like a US medtech for most practical purposes, though currency movements affect its reported European revenue.

In the second quarter of 2026 LivaNova reported revenue of roughly $390.5 million, up about 10.8% year over year, and adjusted earnings per share of roughly $1.26 versus about $1.05 a year earlier, beating consensus on both lines. Cardiopulmonary revenue was about $222 million (up roughly 10%) and epilepsy revenue grew about 10%. The company raised full-year 2026 guidance to 8% to 9% constant-currency revenue growth and $4.30 to $4.40 in adjusted EPS.